Please use this identifier to cite or link to this item: http://arl.liuc.it/dspace/handle/2468/6818
Title: Pazienti diabetici di tipo 2, non in terapia insulinica e albumina glicata: una valutazione multidimensionale
Other Titles: Insuline-Naive type 2 diabetic patients: a multidimensional evaluation on the role of glycated albumin
Authors: Ferrario, Lucrezia
Schettini, Fabrizio
Foglia, Emanuela
Avogaro, Angelo
Bellia, Chiara
Bertuzzi, Federico
Bonetti, Graziella
Ceriello, Antonio
Ciaccio, Marcello
Corsi Romanelli, Massimiliano
Dozio, Elena
Falqui, Luca
Girelli, Angela
Nicolucci, Antonio
Perseghin, Gianluca
Plebani, Mario
Valentini, Umberto
Zaninotto, Martina
Croce, Davide
Issue Date: 2020
Publisher: Biomedia
Bibliographic citation: Ferrario Lucrezia, et al. (2020), Pazienti diabetici di tipo 2, non in terapia insulinica e albumina glicata: una valutazione multidimensionale = Insuline-Naive type 2 diabetic patients: a multidimensional evaluation on the role of glycated albumin. In: Biochimica clinica, vol. 44, n. 1, March 2020, p. 52-60. ISSN 0393-0564. DOI 10.19186/BC_2019.049.
Abstract: Insuline-Naaïve type 2 diabetic patients: a multidimensional evaluation on the role of glycated albumin Introduction: glycated Albumin (GA) is an innovative glycemic marker, that could be used in the clinical practice, as an add-on strategy, to the traditional glycemic monitoring systems, such as glycated haemoglobin (Hb1Ac) and fasting plasma glucose (FPG). The study aims at presenting the results of a multidimensional analysis conducted in Italy, exploring the main clinical, economic, ethical, social and organizational implications, related to the introduction of GA. Methods: an Health Technology Assessment (HTA) approach was implemented. The analysis considered the Italian National Healthcare Service (NHS) perspective, and assumed a 12-month time horizon, focusing on type 2 diabetes patients insulin-naïve, assuming oral therapy. The 9 HTA dimensions (derived from the Core Model developed by the European Network of HTA – EUnetHTA) were deployed, considering scientific evidence, health economics tools and qualitative approaches, through the administration of specific questionnaires to 15 diabetes experts. Results: literature reported better GA safety and efficacy profiles, thus being a predictor of the relative risk for diabetes complications development, and increasing the therapeutic success after 3 months of therapy (97.0% versus 71.6%). From an economic point of view, GA introduction resulted in an economic advantage of 1.06% and in a better tradeoff between costs sustained and efficacy gained. Considering a 7-item Likert Scale (ranging from -3 to +3), negative perceptions emerged with regard to equity aspects (0.13 versus 0.72) due to GA limited accessibility, whereas it would improve both patients (2.17 versus 1.33) and care givers (1.50 versus 0.83) quality of life. In the short term, GA required training courses and equipment update, whereas, in the long term, it could be considered the preferable solution from an organizational perspective (0.30 Conclusions: the results of this study demonstrated GA strategic relevance, its economic sustainability and feasibility, versus 0.01). as well as the potential clinical pathway improvement.
URI: http://arl.liuc.it/dspace/handle/2468/6818
Journal/Book: Biochimica clinica
ISSN: 0393-0564
Appears in Collections:Contributo in rivista

Files in This Item:
File Description SizeFormat 
6818.pdf
  Restricted Access
329,53 kBAdobe PDFView/Open Request a copy


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.